Grifols, S.A. (GIKLY)
USD 5.13
(0.0%)
USD 5.13
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 8.21 Billion EUR | -9.41% |
| 2022 | 9.06 Billion EUR | 30.86% |
| 2021 | 6.93 Billion EUR | 5.13% |
| 2020 | 6.59 Billion EUR | -2.86% |
| 2019 | 6.78 Billion EUR | 12.72% |
| 2018 | 6.02 Billion EUR | 2.42% |
| 2017 | 5.87 Billion EUR | 25.57% |
| 2016 | 4.68 Billion EUR | 2.39% |
| 2015 | 4.57 Billion EUR | 12.29% |
| 2014 | 4.07 Billion EUR | 67.01% |
| 2013 | 2.43 Billion EUR | -5.72% |
| 2012 | 2.58 Billion EUR | -7.95% |
| 2011 | 2.8 Billion EUR | 322.2% |
| 2010 | 665.38 Million EUR | -5.38% |
| 2009 | 703.18 Million EUR | 117.0% |
| 2008 | 324.05 Million EUR | 71.02% |
| 2007 | 189.48 Million EUR | -4.46% |
| 2006 | 198.32 Million EUR | 4.39% |
| 2005 | 189.99 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 9.65 Billion EUR | 17.47% |
| 2024 Q2 | 6.93 Billion EUR | -19.93% |
| 2023 Q4 | 8.21 Billion EUR | -20.24% |
| 2023 Q3 | 10.29 Billion EUR | 0.95% |
| 2023 Q1 | 9.99 Billion USD | 10.25% |
| 2023 Q2 | 10.2 Billion EUR | 2.04% |
| 2023 FY | 8.21 Billion EUR | -9.41% |
| 2022 Q4 | 9.06 Billion USD | 11.22% |
| 2022 FY | 9.06 Billion EUR | 30.86% |
| 2022 Q2 | 9.15 Billion EUR | 0.0% |
| 2022 Q3 | 8.15 Billion EUR | -10.93% |
| 2022 Q1 | - EUR | -100.0% |
| 2021 Q1 | 6.73 Billion EUR | 2.11% |
| 2021 Q2 | 6.7 Billion EUR | -0.37% |
| 2021 Q3 | 7.76 Billion EUR | 15.82% |
| 2021 FY | 6.93 Billion EUR | 5.13% |
| 2021 Q4 | 7.76 Billion USD | 0.0% |
| 2020 FY | 6.59 Billion EUR | -2.86% |
| 2020 Q4 | 6.59 Billion EUR | -2.03% |
| 2020 Q3 | 6.72 Billion EUR | -0.81% |
| 2020 Q2 | 6.78 Billion EUR | -1.17% |
| 2020 Q1 | 6.86 Billion EUR | 1.14% |
| 2019 Q4 | 6.78 Billion EUR | -1.7% |
| 2019 FY | 6.78 Billion EUR | 12.72% |
| 2019 Q1 | 6.86 Billion EUR | 14.01% |
| 2019 Q2 | 6.66 Billion EUR | -2.94% |
| 2019 Q3 | 6.9 Billion EUR | 3.63% |
| 2018 Q1 | 5.82 Billion EUR | -0.86% |
| 2018 FY | 6.02 Billion EUR | 2.42% |
| 2018 Q4 | 6.02 Billion EUR | -1.56% |
| 2018 Q3 | 6.11 Billion EUR | 2.69% |
| 2018 Q2 | 5.95 Billion EUR | 2.2% |
| 2017 Q4 | 5.87 Billion EUR | -0.19% |
| 2017 Q2 | 6.01 Billion EUR | -4.95% |
| 2017 FY | 5.87 Billion EUR | 25.57% |
| 2017 Q1 | 6.33 Billion EUR | 35.29% |
| 2017 Q3 | 5.88 Billion EUR | -2.16% |
| 2016 Q4 | 4.68 Billion EUR | 5.1% |
| 2016 Q2 | 4.48 Billion EUR | 2.11% |
| 2016 FY | 4.68 Billion EUR | 2.39% |
| 2016 Q1 | 4.38 Billion EUR | -4.0% |
| 2016 Q3 | 4.45 Billion EUR | -0.62% |
| 2015 FY | 4.57 Billion EUR | 12.29% |
| 2015 Q4 | 4.57 Billion EUR | 4.76% |
| 2015 Q3 | 4.36 Billion EUR | -0.24% |
| 2015 Q2 | 4.37 Billion EUR | -3.63% |
| 2015 Q1 | 4.53 Billion EUR | 11.49% |
| 2014 Q3 | 3.94 Billion EUR | 7.49% |
| 2014 Q2 | 3.67 Billion EUR | 0.42% |
| 2014 FY | 4.07 Billion EUR | 67.01% |
| 2014 Q1 | 3.65 Billion EUR | 49.91% |
| 2014 Q4 | 4.07 Billion EUR | 3.21% |
| 2013 Q1 | 2.63 Billion EUR | 2.01% |
| 2013 Q2 | 2.57 Billion EUR | -2.36% |
| 2013 FY | 2.43 Billion EUR | -5.72% |
| 2013 Q3 | 2.49 Billion EUR | -2.99% |
| 2013 Q4 | 2.43 Billion EUR | -2.42% |
| 2012 Q1 | 2.56 Billion EUR | -8.74% |
| 2012 Q4 | 2.58 Billion EUR | -1.94% |
| 2012 Q3 | 2.63 Billion EUR | -2.42% |
| 2012 FY | 2.58 Billion EUR | -7.95% |
| 2012 Q2 | 2.7 Billion EUR | 5.41% |
| 2011 Q4 | 2.8 Billion EUR | -1.02% |
| 2011 Q2 | 2.64 Billion EUR | 0.0% |
| 2011 FY | 2.8 Billion EUR | 322.2% |
| 2011 Q3 | 2.83 Billion EUR | 7.39% |
| 2010 Q4 | 665.38 Million EUR | 0.0% |
| 2010 FY | 665.38 Million EUR | -5.38% |
| 2009 FY | 703.18 Million EUR | 117.0% |
| 2008 FY | 324.05 Million EUR | 71.02% |
| 2007 FY | 189.48 Million EUR | -4.46% |
| 2006 FY | 198.32 Million EUR | 4.39% |
| 2005 FY | 189.99 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.33 Billion USD | 63.215% |
| Bristol-Myers Squibb Company PFD CONV 2 | 38.18 Billion USD | 78.484% |
| CSPC Pharmaceutical Group Limited | 107.05 Million USD | -7573.688% |
| Clarus Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Novartis AG | 20.03 Billion USD | 58.993% |
| PT Kalbe Farma Tbk. | 19.39 Million USD | -42264.589% |